Serum Institute of India CEO Adar Poonawalla said that SII has decided to revise the price of Covishield vaccine for private hospitals after discussions with the Central government.
The recommendation for Covishield is yet to be implemented in the national COVID-19 vaccination programme.
With cases remaining on the higher side, both in hospitalisation and mortalities, USA will soon launch Omicron-specific vaccine in March
The DCGI approval came after the SEC on COVID-19 of the CDSCO on January 19 recommended granting regular market approval to the SII's Covishield and Bharat Biotech's Covaxin for use in adult population subject to certain conditions.
Hyderabad-based Bharat Biotech had submitted complete information on chemistry, manufacturing, and controls, along with the pre-clinical and clinical data while seeking regular market authorisation for Covaxin.
The cumulative COVID-19 vaccine doses administered in the country have reached 158.74 crore so far, the Union Health Ministry said on Tuesday.
Vaccine-induced or Hybrid immunity reduces re-infection chances for 9-10 months only
The study provides comprehensive data on the real-world vaccine effectiveness and immunological response to vaccination which should help guide policy. The study thus implies that the vaccines continued to be effective in protecting against severe disease and death regardless of the variants.
According to the source, the Union government has allowed the commercial export of both vaccines - Covishield and Covaxin - in view of sufficient stock of the vaccines available with the states and Union Territories, and also with the manufacturers.
An MoU was signed to recognise Covid-19 vaccine certification by India's Ambassador to Nepal Vinay Mohan Kwatra and the Himalayan nation's Health Secretary on Tuesday.
Of eight WHO-approved vaccines against Covid-19 in emergency use listing, two vaccines -- Covaxin and Covishield -- are from India.
Covishield, the India-manufactured Oxford-AstraZeneca COVID-19 vaccine, was added to the UK's approved list last month.
Five more countries on Monday recognised India's vaccine certificate, after Australia recognised Bharat Biotech's Covaxin for allowing entry of travellers who had received the vaccine
The top court told the petitioner's counsel that it finds no error with the high court decision in the matter, and it will not entertain the petition.
There is no difference in antibodies produced by Covaxin and Covishield vaccines against the Covid-19 virus. This information was shared by Odisha Health Services Director Bijay Mohapatra on Monday (Sept 27).
We are engaging with the Government of India to explore how we could expand UK recognition of vaccine certification to people vaccinated by a relevant public health body in India, said a British High Commission spokesperson.
Stating that there is no shortage of vaccines in the country, the source said that the Centre is capable of supplying as many vaccine doses the states need, in real-time without any delay.
The government in May had further extended the gap between the two doses of Covishield from 6-8 weeks to 12-16 weeks and said the decision to increase the gap was based on scientific evidence.
As per a BBC report, the World Health Organisation (WHO) has identified counterfeit versions of India's primary Covid vaccine, Covishield
These findings have an important implication for the COVID-19 vaccination program wherein heterologous immunisation will pave the way for induction of improved and better protection against the variant strains of SARS-CoV-2.
The Department of Biotechnology under the Ministry of Science and Technology has launched 'Mission COVID Suraksha- the Indian COVID-19 Vaccine Development Mission'.
"If an Indian citizen beneficiary has taken first dose of Covishield or AstraZeneca (ChAdOx1 nCov-19) vaccine outside India, the beneficiary can register on CoWIN app at the time of taking the second dose of Covishield vaccine after prescribed time interval and details of first dose can be recorded on the CoWIN app at the same time."
The State Health Department of Odisha has requested the Centre to allocate the balance Covid vaccine doses under private hospitals share to the State government.
The State government of Odisha on Friday announced to introduce Covaxin for inoculation of people aged 18 years and above in the district of Ganjam. Manufactured by the Bharat Biotech will be soon rolled out for vaccinating people in Ganjam district including the Berhampur Municipal Corporation area from the month of July.
The Odisha government on Wednesday stopped the COVID-19 vaccination drive in 11 districts due to an "acute shortage" of Covishield doses
The State Health Department of Odisha has appealed to the people to take Covid-19 vaccine shot as early as possible and adhere to the appropriate Covid protocols ahead of a possible third wave of the pandemic that has already hit other countries.
As per experts, a vaccine will be considered a marathoner protector if it is able to produce good spike protein antibodies. A spike protein antibody test can confirm whether claims made by Covisheild and Covaxin are true
On the decision to increase the gap between two doses of Covishield from four-six weeks to 12-16 weeks, he said the move was based on scientific decision and there was no dissenting voice among the National Technical Advisory Group on Immunisation (NTAGI) members.
The maximum price of Covishield for private COVID-19 Vaccination Centres (CVCs) has been fixed at Rs 780 per dose, while that of Covaxin is Rs 1,410 per dose and Sputnik V Rs 1,145 per dose, it said.
Noting that 60 per cent to 70 per cent of the children who got infected and got admitted in hospitals during the second wave in India, had either comorbidities or low immunity, the All India Institute of Medical Sciences (AIIMS) Director said that healthy children recovered with mild illness without need for hospitalisation.
The series of lockdowns and shutdowns enforced by the State government of Odisha has really fructified results as anticipated, DMET CBK Mohanty said today.
A latest study has found that both vaccines, Covishield and Covaxin elicited a good immune response after two doses, although seropositivity rates and the median anti-spike antibody titre was significantly higher in Covishield as compared to Covaxin.
Vaccine manufacturer, Serum Institute of India (SII) has applied to the Drugs Controller General of India (DCGI) seeking permission to manufacture Russian COVID vaccine Sputnik V in India. As per sources, the Pune-based vaccine maker has also sought permission for test analysis and examination.
The Odisha Health and Family Welfare Department on Wednesday issued advisory for the physicians and beneficiaries to report suspected Thrombosis after Covishield vaccine administration.
The Union government has reiterated to the states/UTs that online appointments booked for second dose of Covishield prior to this change of the interval between the two doses of Covishield, must be honoured.
Gap between two doses of Covishield vaccine increased. A day after the Union Health ministry increased the gap between 2 doses of Covishield, Odisha announced the changes. Union Health Ministry widened the gap between 2 doses of Covishield from 42 days (6 weeks) to 84 days
The Ministry of Health and Family Welfare (MoHFW) had on Thursday widened the gap between two doses of Serum Institute of India’s Covidshield vaccine from 42 days (6 weeks) to 84 days (12weeks).
The Centre on Thursday approved extending the gap between the two doses of the Covishield vaccine from 6-8 weeks to 12-16 weeks.
A government panel has recommended increasing the gap between two doses of Covishield COVID-19 vaccine to 12-16 weeks and said that pregnant women may be offered the choice to take any vaccine
The Centre has told the Supreme Court that no governmental aid, assistance or grant was made either for research or development of either Covaxin or Covishield vaccines but some financial assistance was given for conducting clinical trials.
LIVE TV
